The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Study determines factors affecting decisions regarding active surveillance in low-risk prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A study examined the rates of active surveillance use and evaluated the factors associated with selecting this management strategy over surgery or radiation in low-risk prostate cancer, with a focus on underserved Black patients who have been underrepresented in prior studies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.
In Brief

Northwestern Mutual to support childhood cancer survivors, siblings with $500,000 in college scholarships

Northwestern Mutual, through its Foundation, announced a class of scholars from its annual Childhood Cancer Scholarship Program for families affected by childhood cancer. The program provides scholarships to students affected by a diagnosis—either as survivors themselves or as siblings—enabling recipients to chase their dreams and transform their experience into purpose.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account